21![ASX ANNOUNCEMENT 14 October 2015 Cynata to Investigate Cell Therapy for Cancer in Major New Collaboration ASX ANNOUNCEMENT 14 October 2015 Cynata to Investigate Cell Therapy for Cancer in Major New Collaboration](https://www.pdfsearch.io/img/3f21ff951c0aae8dd8e544efe98de978.jpg) | Add to Reading ListSource URL: cynata.com- Date: 2016-03-08 18:52:12
|
---|
22![A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R, A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,](https://www.pdfsearch.io/img/88f272afabb8e04adaa2abfaf175b315.jpg) | Add to Reading ListSource URL: s3.amazonaws.com- Date: 2014-09-25 16:14:56
|
---|
23![NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3) NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3)](https://www.pdfsearch.io/img/611b17e4b18460253b2bb803c8d656c2.jpg) | Add to Reading ListSource URL: posters.omed.s3.amazonaws.com- Date: 2015-12-11 14:21:05
|
---|
24![Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in](https://www.pdfsearch.io/img/08ca2e6f5c3c8c546120cdc814c9e1a5.jpg) | Add to Reading ListSource URL: posters.omed.s3.amazonaws.com- Date: 2015-06-12 10:36:45
|
---|
25![Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain](https://www.pdfsearch.io/img/3ef655b78a357da7f37cda9e756021df.jpg) | Add to Reading ListSource URL: posters.omed.s3.amazonaws.com- Date: 2015-11-04 11:34:18
|
---|
26![Phase 1b Trial of Tarextumab (OMP 59R5) (anti-Notch 2/3 antibody) in Combination with Etoposide and Cisplatin (EP) in Patients (pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (ED-SCLC): PINNACLE Study M Cathe Phase 1b Trial of Tarextumab (OMP 59R5) (anti-Notch 2/3 antibody) in Combination with Etoposide and Cisplatin (EP) in Patients (pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (ED-SCLC): PINNACLE Study M Cathe](https://www.pdfsearch.io/img/3abd042d944c27154c43a660a3cb407f.jpg) | Add to Reading ListSource URL: s3.amazonaws.com- Date: 2014-09-25 16:16:58
|
---|
27![NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3) NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3)](https://www.pdfsearch.io/img/31c87762a5903e364e04c37fd2467273.jpg) | Add to Reading ListSource URL: posters.omed.s3.amazonaws.com- Date: 2016-02-21 23:46:50
|
---|
28![A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years) A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)](https://www.pdfsearch.io/img/ba6b1bf28a642b8b3ab10702e3e17485.jpg) | Add to Reading ListSource URL: posters.omed.s3.amazonaws.com- Date: 2016-01-22 10:42:40
|
---|
29![A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM](https://www.pdfsearch.io/img/1bcc18ee72173cd46f6c9066461d80ae.jpg) | Add to Reading ListSource URL: s3.amazonaws.com- Date: 2014-09-25 16:14:56
|
---|
30![Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan](https://www.pdfsearch.io/img/459396a902a2f44337b4b2ffbe2778a4.jpg) | Add to Reading ListSource URL: posters.omed.s3.amazonaws.com- Date: 2015-11-04 11:34:26
|
---|